Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method

Constipation Clinical Trial

Official title:

Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00563615
• Other study ID #: KW/FR/03-030
• Secondary ID: HARECCTR0500026
• Status: Recruiting
• Phase: N/A
• First received: November 21, 2007
• Last updated: July 6, 2010
• Start date: November 2004
• Est. completion date: October 2006

Study information

• Verified date: July 2010
• Source: Hospital Authority, Hong Kong
• Contact: Ambrose CP Kwan, Dr
• Phone: (852) 2990 1111
• Email: argylest[@]netvigator.com
• Is FDA regulated: No
• Health authority: Hong Kong: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Functional constipation is a common problem in Hong Kong. In a recent telephone survey, the prevalence of constipation as defined by Rome II criteria was 14%. Apart from organic, metabolic, neurological and drug induced causes, constipation most often arises from 2 disorders of colorectal motility: slow transit constipation or pelvic floor dysfunction or both. In the position statement from the American Gastroenterological Association , colon transit study was recommended to differentiate slow transit constipation from pelvic floor dysfunction. The management algorithm for normal transit and slow transit constipation was different and surgery should be considered for patients with slow transit constipation. In a recent paper by Bonapace , scintigraphy could be used to study both gastric, small bowel and large bowel transit time. The clinical diagnosis was changed in 51% of cases of constipation after scintigraphy and patient management such as adding a prokinetic agent, referral to biofeedback center, decision on surgery was affected in 64% of cases.

Tegaserod is a recently approved prokinetic agent to be marketed in Hong Kong for the management of patients with constipation predominant irritable bowel syndrome (C-IBS). In a paper from Mayo clinic based on scintigraphic examination, tegaserod 2mg bd accelerates orocaecal transit in C-IBS patients. However studies in functional constipation basing on tegaserod 6 mg twice daily has not been published yet. Therefore, the Gastroenterology team and nuclear medicine teams of Princess Margaret Hospital, Gastroenterology teams of Caritas Medical Center and Yan Chai Hospital decide to study small and large bowel transit in functional constipation patients by scintigraphy. The efficacy of tegaserod in improving bowel transit is also examined in this randomized double blind placebo controlled study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: October 2006
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• History of functional constipation as proposed by the Rome II Criteria and the usual frequency of spontaneous bowel motion must be equal or less than 2 times /week.

• An endoscopic/radiologic bowel evaluation (colonoscopic examination and/or a sigmoidoscopy + barium enema) is required in patients older than 40 years. This evaluation must have been performed within the past 5 years. In addition, there should not be history or evidence of weight loss, anemia or rectal bleeding since the evaluation was performed.

Note: For patients who require these procedures, these tests should be performed after the patient has signed informed consent and at least 7 days PRIOR to the start of the diaries (washout period). The 7-day window is to allow the patient to recuperate prior to collecting baseline data.

A copy of the report should be placed in the patient source document.

• Patients who are able to communicate well with the investigator and to comply with the requirements for the entire study, including the withdrawal period.

• Patients who provide written informed consent before participating in the study after being given a full description of the study.

Exclusion Criteria:

• Medications known to affect gastrointestinal transit before 1 week of the treatment phase of the study.

• With clinical evidence (including physical exam, vital signs, ECG, laboratory tests) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematology, endocrine or metabolic disorders, neurologic disease, or of any disease that may interfere with the patient successfully completing the study.

• Existence of surgical or medical conditions which interfere with the absorption, distribution, metabolism and excretion of the study medication.

• With hypo or hyper thyroidism (clinically significant abnormal TSH level at screening).

• With symptoms of a significant clinical illness in the two weeks preceding baseline.

• With other relevant intercurrent medical condition that may interfere with the objectives of the study.

• Women who are pregnant or breast-feeding.

• With evidence or history of drug or alcohol abuse within the past 12 months.

• Who received another investigational drug within the 30 days prior to entry in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Constipation

Intervention

Drug:
• Tegaserod

Locations

Country	Name	City	State
China	Caritas Medical Centre	Hong Kong
China	Princess Margaret Hospital	Hong Kong
China	Yan Chai Hospital	Hong Kong

Sponsors (2)

Lead Sponsor	Collaborator
Hospital Authority, Hong Kong	Novartis Pharmaceuticals

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Small and large bowel transit time		2 weeks after treatment

External Links

•   HAREC Clinical Trial Registry